Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
OBJECTIVE
Eugenosedin-A is a serotonin (5-hydroxytryptamine; 5-HT) 5-HT(1B/2A) and alpha(1)/alpha(2)/beta(1)-adrenoceptor blocker with anti-oxidative, anti-inflammatory and free-radical scavenging activities. Previous reports demonstrated that 5-HT(2A) blockers could diminish hyperlipidaemia. This study therefore aimed to investigate the possible uses and mechanisms of eugenosedin-A and other agents in treating hyperlipidaemia.


METHODS
C57BL/6J mice were randomly divided into seven groups, fed a regular diet or a high-fat diet alone or supplemented with one of five agents: eugenosedin-A, ketanserin, prazosin, propranolol or atorvastatin (5 mg/kg p.o.) for 8 weeks.


RESULTS
Compared with the regular diet, the mice fed the high-fat diet had significantly higher body weight and glucose, insulin and lipid levels. Brain malondialdehyde concentration was increased and liver glutathione peroxidase activity decreased. Addition of eugenosedin-A to the high-fat diet resulted in less weight gain and reduced hyperglycaemia, hyperinsulinaemia and hyperlipidaemia. Lipid and glucose homeostasis were related to decreased hepatic lipogenesis mRNAs and proteins (sterol regulatory element binding protein 1a, fatty acid synthase, sterol-CoA desaturase) and restored adipose peroxisome proliferator-activated receptor gamma expression. Eugenosedin-A also enhanced low-density lipoprotein receptor mRNA expression.


CONCLUSIONS
Eugenosedin-A may improve plasma lipid metabolism by increasing low-density lipoprotein receptor and peroxisome proliferator-activated receptor gamma expression and diminishing sterol regulatory element binding protein 1a, fatty acid synthase and sterol-CoA desaturase. Reduction of plasma glucose and lipid levels may, in turn, reduce insulin concentration, which would explain the marked improvement in obesity-related hyperglycaemia and hyperlipidaemia. Furthermore, eugenosedin-A affected malondialdehyde concentration and glutathione peroxidase activity, suggesting it may have anti-peroxidation effects in mice fed a high-fat diet.
Shen
Kuo-Ping
KP
Department of Early Childhood Care and Education, Meiho Institute of Technology, Pingtung, Taiwan.
Lin
Hui-Li
HL
Hsieh
Su-Ling
SL
Kwan
Aij-Lie
AL
Chen
Ing-Jun
IJ
Wu
Bin-Nan
BN
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D000069059:Atorvastatin; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D004041:Dietary Fats / Q000494:pharmacology*; D005260:Female; D005979:Glutathione Peroxidase / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology; D006943:Hyperglycemia / Q000517:prevention & control*; D006949:Hyperlipidemias / Q000517:prevention & control*; D007328:Insulin / Q000097:blood; D007650:Ketanserin / Q000494:pharmacology; D015227:Lipid Peroxidation / Q000187:drug effects*; D050155:Lipogenesis / Q000235:genetics; D008099:Liver / Q000378:metabolism; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011224:Prazosin / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D001786:Blood Glucose; D004041:Dietary Fats; D006538:Heptanoic Acids; D007328:Insulin; D047495:PPAR gamma; D010879:Piperazines; D011758:Pyrroles; C496985:eugenosedin-A; D008315:Malondialdehyde; D007650:Ketanserin; D011433:Propranolol; D000069059:Atorvastatin; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D011224:Prazosin